FDA Matters has been disappointed by many others-industry, patients, Congress, media, and think-tanks-who have emphasized agency bashing at their meetings and in their public communications.
The bashing starts with the wrong premise (the agency is largely broken) and concludes with the wrong prescription (break down the agency's culture and processes and rebuild anew).